Colorectal Cancer Screening Blood Test - Advanced Cancer Care
What is a Colorectal Cancer Screening Blood Test?
A colorectal cancer screening blood test is designed to detect early signs of colorectal cancer through analysis of specific markers or genetic material circulating in the blood. This screening blood test for colorectal cancer offers a less invasive alternative compared to traditional stool-based screening or colonoscopic visual examination, helping in the early identification of potential malignancies.
Why Colorectal Cancer Screening Blood Test Is Important
Early detection through colorectal cancer screening blood tests significantly improves treatment success and reduces mortality. These tests detect circulating tumor DNA or abnormal proteins released by cancer cells into the bloodstream. By identifying colorectal cancer before symptoms arise, screening blood tests enable timely intervention, ultimately enhancing survival rates.
Who Should Get a Colorectal Cancer Screening Blood Test?
Colorectal cancer screening blood tests are generally recommended for individuals aged 45 and older who are at average risk. People with a family history of colorectal cancer, genetic predispositions, or other risk factors may require earlier or more frequent blood test screening. Depending on risk profiles and test type, testing frequency may range from annually to every two years.
Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.
How is a Colorectal Cancer Screening Blood Test Performed?
The colorectal cancer screening blood test procedure is minimally invasive and straightforward. A blood sample is drawn from a vein, usually in the arm, and sent to a laboratory for analysis. The blood is tested for cancer-specific biomarkers such as methylated SEPT9 DNA or circulating tumor DNA. No special patient preparation is required, and test results are commonly available within a few days to a week.
Why Choose Everhope for Colorectal Cancer Screening Blood Test
FAQs
Yes, these tests can detect colorectal cancer by identifying circulating tumor DNA and abnormal biomarker patterns, making them effective for early cancer detection. However, they are complementary to stool tests and colonoscopy, not replacements.
FDA-approved tests like the methylated SEPT9 DNA test (Epi proColon) are available. Newer blood tests examining cell-free DNA and other biomarkers are currently in development.
Costs vary by test type, facility, and location but generally are moderately priced. Insurance coverage differs, so patients should verify with their healthcare providers and insurers.
The procedure requires only a simple venous blood draw, usually without special preparation. The sample is analyzed in a lab for tumor-related markers.
These tests are sensitive in detecting colorectal cancer but may miss some precancerous lesions. They are best used as part of a comprehensive screening strategy alongside other tests.